Tech Company Financing Transactions
iECURE Funding Round
iECURE, based in Philadelphia, scored $50 million from OrbiMed, Versant Ventures and private investors.
Transaction Overview
Company Name
Announced On
9/10/2021
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series A
Investors
OrbiMed (Lead Investor) (Stephen Squinto)
Versant Ventures (Lead Investor) (Thomas Woiwode)
Proceeds Purpose
The funds will be used to advance iECURE's pipeline of up to 13 programs, all of which benefit from gene editing and in vivo delivery approaches being developed in the laboratory of James Wilson, M.D., Ph.D., of the University of Pennsylvania Gene Therapy Program (GTP).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Philadelphia, PA 19019
USA
Philadelphia, PA 19019
USA
Phone
Website
Email Address
Overview
We are a mutation-agnostic in vivo gene insertion company striving to cure liver disorders with high unmet need by harnessing new advancements in genetic medicine. Our in vivo insertion methods knock-in healthy copies of disease-causing genes, offering long-term, stable expression of those genes in patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joseph Truitt
Chief Operating Officer
Paul Firuta
VP - Bus. Development
Alex Monteith
Browse more venture capital transactions:
Prev: 9/10/2021: Snyk venture capital transaction
Next: 9/10/2021: Mammoth Biosciences venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record every notable VC transaction. VC transactions reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs